Arana files IND

By Dylan Bushell-Embling
Tuesday, 30 September, 2008

Arana Therapeutics [ASX: AAH] has submitted an IND to the FDA for its candidate ART621 for rheumatoid arthritis.

As part of the IND application, a Phase II dose trial of the anti-TNF drug will be conducted in a multi-centre trial in 200 patients.

Arana expects to begin recruitment for the study later this year, pending approval from the FDA. Quintiles has been named as the contract research manager.

Breast augmentation procedure uses 3D-printed scaffolds

3D-printed scaffold technology from medtech company BellaSeno has been used in a primary breast...

Victoria detects H5N1 avian influenza strain

It follows disease confirmation in seabirds in WA, SA, NSW and Qld and the national decision that...

TGA acts on melatonin imports with infringement notices totalling $99K

Laboratory testing of several imported unregistered melatonin products has confirmed them to be...

Content from other channels on our network

foodpro wrap-up: the event welcomed over 10,000 visitors

interpack China to partner with AIP

Food and beverage businesses get ready for AI future

Nanoantibody technology to address aquaculture challenges

Just a dash of protein enrichment for tomato sauce

The accelerating decline of fieldbus as Ethernet takes over

ANSTO celebrates 20 years of OPAL supporting research and innovation

Engineers Australia marks International Youth Day

Tomago Aluminium smelter gets green investment

The advantages of using intrinsic safety in hazardous locations

"Migrant worker exploitation" sees NSW aged care provider repay nearly $120K

A Day in the Life of a birth suite ANUM

Professor Andrea Driscoll MACN wins 2026 Nursing Trailblazers Award

Do new AI models reproduce gender and racial stereotypes in medicine?

Small decisions. System-wide impact: Where sustainability and healthcare operations meet